Novartis AG (NVSEF)
| Market Cap | 228.98B |
| Revenue (ttm) | 55.19B |
| Net Income (ttm) | 13.65B |
| Shares Out | n/a |
| EPS (ttm) | 6.85 |
| PE Ratio | 16.77 |
| Forward PE | 13.86 |
| Dividend | 3.97 (3.35%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 200 |
| Average Volume | 48,966 |
| Open | 112.58 |
| Previous Close | 111.38 |
| Day's Range | 112.44 - 112.58 |
| 52-Week Range | 94.70 - 126.34 |
| Beta | 0.53 |
| RSI | 36.05 |
| Earnings Date | Jul 17, 2025 |
About CALT
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in EUR Financial StatementsNews
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic car...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...
Matchpoint in pact with Novartis for inflammatory disease treatments
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestones...
Novartis AG 2025 Q2 - Results - Earnings Call Presentation
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Novartis CEO: We're in open discussions with the Trump administration
Novartis CEO Vas Narasimhan said Thursday that the company is in open discussions with the Trump administration over pharmaceutical tariffs, aiming to strike a balance between lowering patient costs a...
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook
Novartis raises outlook on strong second-quarter sales
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Sales of breast cancer drug Kisqali grew 100% in the U.S. in the three months to June.
Novartis raises outlook on strong second-quarter sales
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses
Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.